Obstet Gynecol Sci.  2025 Jan;68(1):18-29. 10.5468/ogs.24180.

Recent development of nanotechnology-based approaches for gynecologic cancer therapy

• Gedda G
• Park YJ
• Pang MG

• KMID: 2563935
• DOI: http://doi.org/10.5468/ogs.24180

Abstract

Gynecological cancer is a life-threatening malignancy among women. Traditional therapies, including chemotherapy, often face challenges in terms of chemotherapeutic drug solubility and resistance, specificity, tumor site targeting, and toxicity to healthy tissues, leading to shortened efficacy and unfavorable patient outcomes and survival rates in patients with gynecologic malignancies. Recently, nanotechnology-based therapeutic methods such as targeted drug delivery and phototherapies have emerged as an appropriate alternative to overcome issues associated with traditional therapeutic methods. Specifically, nanomaterials and nanomaterial-based methods enhance the delivery of therapeutic/targeting agents to tumor sites and cellular uptakes and improve the tumor-suppressing effect. This review aims to provide an overview and future perspective on the potential impact of nanotechnology-based therapeutic methods for effective therapies for gynecologic cancer.

Keyword

Gynecology; Nanotechnology; Drug delivery system; Photodynamic therapy; Photothermal therapy

Figure

• 

  Fig. 1. Mechanisms of chemoresistance in ovarian cancer cells (created with BioRender.com). GSH, glutathione.

• 

  Fig. 2. Schematic illustration of nanotechnology treatment methods for gynecologic cancers (created with BioRender.com). ROS, reactive oxygen species.

Reference

References

1. Piechocki M, Koziołek W, Sroka D, Matrejek A, Miziołek P, Saiuk N, et al. Trends in incidence and mortality of gynecological and breast cancers in Poland (1980-2018). Clin Epidemiol. 2022; 14:95–114.

2. Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015; 16:928–36.

3. Menczer J. Diagnosis and treatment delay in gynecological malignancies. Does it affect outcome? Int J Gynecol Cancer. 2000; 10:89–94.

4. Makker V, MacKay H, Ray-Coquard I, Levine DA, Westin SN, Aoki D, et al. Endometrial cancer. Nat Rev Dis Primer. 2021; 7:88.

5. Jeerakornpassawat D, Suprasert P. Potential predictors for chemotherapeutic response and prognosis in epithelial ovarian, fallopian tube and primary peritoneal cancer patients treated with platinum-based chemotherapy. Obstet Gynecol Sci. 2020; 63:55–63.

6. Hornyak GL, Moore JJ, Tibbals HF, Dutta J. Fundamentals of nanotechnology. 1st ed. Boca Raton: CRC press;2018.

7. Rao CNR, Cheetham AK. Science and technology of nanomaterials: current status and future prospects. J Mater Chem. 2001; 11:2887–94.

8. Gopal J, Wu HF, Gangaraju G. Quantifying the degradation of extracellular polysaccharides of Escherichia coli by CdS quantum dots. J Mater Chem. 2011; 21:13445–51.

9. MKhan MS, Gedda G, Gopal J, Wu HF. Probing the cytotoxicity of CdS–MPA and CdSe–MUA QDs on the bacterial pathogen Staphylococcus aureus using MALDI-MS. Analytical Methods. 2014; 6:5304–13.

10. Gedda G, Wu HF. Fabrication of surface modified ZnO nanorod array for MALDI-MS analysis of bacteria in a nanoliter droplet: a multiple function biochip. Sens Actuator B-Chem. 2019; 288:667–77.

11. Zulfajri M, Gedda G, Ulla H, Gollavelli G, Huang GG. A review on the chemical and biological sensing applications of silver/carbon dots nanocomposites with their interaction mechanisms. Adv Colloid Interface Sci. 2024; 325:103115.

12. Talib A, Khan MS, Gedda G, Wu HF. Stabilization of gold nanoparticles using natural plant gel: a greener step towards biological applications. J Mol Liq. 2016; 220:463–7.

13. Wang Y, Du W, Zhang T, Zhu Y, Ni Y, Wang C, et al. A self-evaluating photothermal therapeutic nanoparticle. ACS Nano. 2020; 14:9585–93.

14. Huang Y, Li P, Zhao R, Zhao L, Liu J, Peng S, et al. Silica nanoparticles: biomedical applications and toxicity. Biomed Pharmacother. 2022; 151:113053.

15. Hassan SS, Kamel AH, Hashem HM, Bary EA. Drug delivery systems between metal, liposome, and polymer-based nanomedicine: a review. Eur Chem Bull. 2020; 9:91–102.

16. Yang C, Lin ZI, Chen JA, Xu Z, Gu J, Law WC, et al. Organic/inorganic self-assembled hybrid nano-architectures for cancer therapy applications. Macromol Biosci. 2022; 22:2100349.

17. Yang S, Fei W, Zhao Y, Wang F, Ye Y, Wang F. Combat against gynecological cancers with blood vessels as entry point: anti-angiogenic drugs, clinical trials and preclinical nano-delivery platforms. Int J Nanomedicine. 2023; 18:3035–46.

18. Lopes-Nunes J, Agonia AS, Rosado T, Gallardo E, Palmeira-de-Oliveira R, Palmeira-de-Oliveira A, et al. Aptamer-functionalized gold nanoparticles for drug delivery to gynecological carcinoma cells. Cancers (Basel). 2021; 13:4038.

19. Ghosh S, Jayaram P, Kabekkodu SP, Satyamoorthy K. Targeted drug delivery in cervical cancer: current perspectives. Eur J Pharmacol. 2022; 917:174751.

20. Luo L, Zhou H, Wang S, Pang M, Zhang J, Hu Y, et al. The application of nanoparticle-based imaging and phototherapy for female reproductive organs diseases. Small. 2024; 20:e2207694.

21. Sánchez-Ramírez DR, Domínguez-Ríos R, Juárez J, Valdés M, Hassan N, Quintero-Ramos A, et al. Biodegradable photoresponsive nanoparticles for chemo-, photothermal- and photodynamic therapy of ovarian cancer. Mater Sci Eng C Mater Biol Appl. 2020; 116:111196.

22. Debnath M, Khan A, Keshari R, Banerjee A, Srivastava R. Impact of stimuli-responsive biomaterials in gynecological cancer therapy. Biomed Mater Devices. 2024; 2:655–68.

23. Kumar L, Pramanik R, Kumar S, Bhatla N, Malik S. Neoadjuvant chemotherapy in gynaecological cancers - implications for staging. Best Pract Res Clin Obstet Gynaecol. 2015; 29:790–801.

24. Cooke SL, Brenton JD. Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol. 2011; 12:1169–74.

25. Wudtisan J, Suprasert P. Micturition symptoms in gynecologic cancer patients receiving paclitaxel and platinum-based chemotherapy regimen: a prospective study. Obstet Gynecol Sci. 2023; 66:34–41.

26. Sanguanwongthong K, Suprasert P. Prevalence of malnourishment and predictive factors associated with the nutritional status of gynecologic cancer patients undergoing chemotherapy: a cross-sectional analysis. Obstet Gynecol Sci. 2022; 65:234–43.

27. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991; 9:389–93.

28. Marchetti C, De Felice F, Romito A, Iacobelli V, Sassu CM, Corrado G, et al. Chemotherapy resistance in epithelial ovarian cancer: mechanisms and emerging treatments. Semin Cancer Biol. 2021; 77:144–66.

29. Amaral MVS, DE Sousa Portilho AJ, DA Silva EL, DE Oliveira Sales L, DA Silva Maués JH, DE Moraes MEA, et al. Establishment of drug-resistant cell lines as a model in experimental oncology: a review. Anticancer Res. 2019; 39:6443–55.

30. Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009; 9:665–74.

31. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979; 63:1727–33.

32. Wicki A, Mandalà M, Massi D, Taverna D, Tang H, Hemmings BA, et al. Acquired resistance to clinical cancer therapy: a twist in physiological signaling. Physiol Rev. 2016; 96:805–29.

33. Lei ZN, Tian Q, Teng QX, Wurpel JND, Zeng L, Pan Y, et al. Understanding and targeting resistance mechanisms in cancer. MedComm (2020). 2023; 4:e265.

34. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014; 740:364–78.

35. Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D’Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015; 5:1137–54.

36. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008; 14:1291–5.

37. Cho KR, Shih IeM. Ovarian cancer. Annu Rev Pathol. 2009; 4:287–313.

38. Burdett NL, Willis MO, Alsop K, Hunt AL, Pandey A, Hamilton PT, et al. Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer. Nat Genet. 2023; 55:437–50.

39. Andrews PA, Howell SB. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells. 1990; 2:35–43.

40. Petris MJ. The SLC31 (Ctr) copper transporter family. Pflugers Arch. 2004; 447:752–5.

41. Holzer AK, Howell SB. The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res. 2006; 66:10944–52.

42. Samimi G, Safaei R, Katano K, Holzer AK, Rochdi M, Tomioka M, et al. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res. 2004; 10:4661–9.

43. Lukanović D, Herzog M, Kobal B, Černe K. The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistance and personalized medicine in ovarian cancer. Biomed Pharmacother. 2020; 129:110401.

44. Redza-Dutordoir M, Averill-Bates DA. Activation of apoptosis signalling pathways by reactive oxygen species. Biochim Biophys Acta Mol Cell Res. 2016; 1863:2977–92.

45. Gamcsik MP, Kasibhatla MS, Teeter SD, Colvin OM. Glutathione levels in human tumors. Biomarkers. 2012; 17:671–91.

46. Chen HH, Kuo MT. Role of glutathione in the regulation of cisplatin resistance in cancer chemotherapy. Met Based Drugs. 2010; 2010:430939.

47. Andrews PA, Murphy MP, Howell SB. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol. 1987; 19:149–54.

48. Ishikawa T, Ali-Osman F. Glutathione-associated cisdiamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem. 1993; 268:20116–25.

49. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 2012; 72:4875–82.

50. Vemula S, Bonala S, Vadde NK, Natu JZ, Basha R, Vadde R, et al. Drug resistance and immunotherapy in gynecologic cancers. Life Sci. 2023; 332:122104.

51. Balch C, Matei DE, Huang TH, Nephew KP. Role of epigenomics in ovarian and endometrial cancers. Epigenomics. 2010; 2:419–47.

52. Abbosh PH, Montgomery JS, Starkey JA, Novotny M, Zuhowski EG, Egorin MJ, et al. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. Cancer Res. 2006; 66:115582–91.

53. Liang XJ, Chen C, Zhao Y, Wang PC. Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol Biol. 2010; 596:467–88.

54. van Vlerken LE, Duan Z, Seiden MV, Amiji MM. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res. 2007; 67:4843–50.

55. Zhang C, Sheng Y, Sun X, Wang Y. New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions. Cancer Metastasis Rev. 2023; 42:891–925.

56. Korzun T, Moses AS, Diba P, Sattler AL, Olson B, Taratula OR, et al. Development and perspectives: multifunctional nucleic acid nanomedicines for treatment of gynecological cancers. Small. 2024; 20:e2301776.

57. Kanchi S, Sharotri N, Chokkareddy R, Sharma D, Hussein FH. Smart nanomaterials for infectious diseases. 1st ed. London: Royal Society of Chemistry;2024.

58. Keyvani V, Mollazadeh S, Riahi E, Mahmoudian RA, Anvari K, Avan A. Nanotechnological advances in the diagnosis of gynecological cancers and nanotheranostics. Curr Pharm Des. 2024; 30:2619–30.

59. Gu X, Wang C. Advancements in nano-immunotherapy for gynecological cancers: a new frontier. Biomed Pharmacother. 2024; 180:117553.

60. Wei H, Hao Y, Zhang J, Qi Y, Feng C, Zhang C. Advances in lysosomal escape mechanisms for gynecological cancer nano-therapeutics. J Pharm Anal. 2024; 14:101119.

61. Sapsford KE, Algar WR, Berti L, Gemmill KB, Casey BJ, Oh E, et al. Functionalizing nanoparticles with biological molecules: developing chemistries that facilitate nanotechnology. Chem Rev. 2013; 113:1904–2074.

62. Yu B, Tai HC, Xue W, Lee LJ, Lee RJ. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol. 2010; 27:286–98.

64. Li K, Xu J, Wang J, Lu C, Dai Y, Dai Q, et al. Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer. Cancer Immunol Immunother. 2023; 72:917–28.

65. Cantillo E, Blanc-Durand F, Leary A, Slomovitz BM, Fuh K, Washington C. Updates in the use of targeted therapies for gynecologic cancers. Am Soc Clin Oncol Educ Book. 2024; 44:e438582.

66. Manchana T, Ittiwut C, Mutirangura A, Kavanagh JJ. Targeted therapies for rare gynaecological cancers. Lancet Oncol. 2010; 11:685–93.

66. Lai TS, Francoeur A, Manrriquez E, Venkat P, Chang A, Douek M, et al. Percutaneous interstitial brachytherapy ablation for targeting oligometastatic gynecologic cancers. Brachytherapy. 2024; 23:266–73.

67. Jin K, Zhang H, Yang Y, Gao Y. Nano-drug delivery systems based on biodegradable polymers for the therapy of gynecological malignancies. Int J Polym Mater Polym Biomater. 2024; 73:1262–77.

68. Acharya B, Behera A, Behera S, Moharana S. Recent advances in nanotechnology-based drug delivery systems for the diagnosis and treatment of reproductive disorders. ACS Appl Bio Mater. 2024; 7:1336–61.

69. Chauhan B, Patel S, Prajapati BG, Singh S. Drug delivery for Alzheimer’s disease using nanotechnology: challenges and advancements. In : Prajapati BG, Chellappan DK, Kendre PN, editors. Alzheimer’s disease and advanced drug delivery strategies. 1st ed. Cambridge: Academic Press;2024. p. 361–71.

70. Zubair M, Riaz M, Kiani MN, Aslam HM, Fatima AEZ, Sultan HM, et al. Application of nanotechnology for targeted drug delivery and nontoxicity. IJGPN. 2024; 2:57–67.

71. Manasa R, Shivananjappa M. Role of nanotechnology-based materials in drug delivery. In : Keservani RK, Kesharwani RK, Sharma AK, editors. Advances in novel formulations for drug delivery. 1st ed. Hoboken (NJ), Beverly (MA): John Wiley & Sons, Inc., ScrivenerPublishing LLC;2023. p. 279–307.

72. Al-Thani AN, Jan AG, Abbas M, Geetha M, Sadasivuni KK. Nanoparticles in cancer theragnostic and drug delivery: a comprehensive review. Life Sci. 2024; 352:122899.

73. Bolla PK, Rodriguez VA, Kalhapure RS, Kolli CS, Andrews S, Renukuntla J. A review on pH and temperature responsive gels and other less explored drug delivery systems. J Drug Deliv Sci Technol. 2018; 46:416–35.

74. Williams L, Hatton FL, Willcock H, Mele E. Electrospinning of stimuli-responsive polymers for controlled drug delivery: pH- and temperature-driven release. Biotechnol Bioeng. 2022; 119:1177–88.

75. Dutta B, Barick KC, Hassan PA. Recent advances in active targeting of nanomaterials for anticancer drug delivery. Adv Colloid Interface Sci. 2021; 296:102509.

76. Gedda G, Pandey S, Khan MS, Talib A, Wu HF. Synthesis of mesoporous titanium oxide for release control and high efficiency drug delivery of vinorelbine bitartrate. RSC Adv. 2016; 6:13145–51.

77. Pandey S, Gedda GR, Thakur M, Bhaisare ML, Talib A, Khan MS, et al. Theranostic carbon dots ‘clathrate-like’nanostructures for targeted photo-chemotherapy and bioimaging of cancer. J Ind Eng Chem. 2017; 56:62–73.

78. Gedda G, Bhupathi A, Tiruveedhi VBG. Naturally derived carbon dots as bioimaging agents. In : Ziyad S, Ibrokhim Y, editors. Biomechanics and functional tissue engineering. 1st ed. London: IntechOpen;2021. p. 1–23.

79. Yao YY, Gedda G, Girma WM, Yen CL, Ling YC, Chang JY. Magnetofluorescent carbon dots derived from crab shell for targeted dual-modality bioimaging and drug delivery. ACS Appl Mater Interfaces. 2017; 9:13887–99.

80. Chiu SH, Gedda G, Girma WM, Chen JK, Ling YC, Ghule AV, et al. Rapid fabrication of carbon quantum dots as multifunctional nanovehicles for dual-modal targeted imaging and chemotherapy. Acta Biomater. 2016; 46:151–64.

81. Dehvari K, Liu KY, Tseng PJ, Gedda G, Girma WM, Chang JY. Sonochemical-assisted green synthesis of nitrogen-doped carbon dots from crab shell as targeted nanoprobes for cell imaging. J Taiwan Inst Chem Eng. 2019; 95:495–503.

82. Irmania N, Dehvari K, Gedda G, Tseng PJ, Chang JY. Manganese-doped green tea-derived carbon quantum dots as a targeted dual imaging and photodynamic therapy platform. J Biomed Mater Res B Appl Biomater. 2020; 108:1616–25.

83. Gedda G, Chen GR, Yao YY, Girma WM, Li JD, Yen CL, et al. Aqueous synthesis of dual-targeting Gd-doped CuInS 2/ZnS quantum dots for cancer-specific bi-modal imaging. New J Chem. 2017; 41:14161–70.

84. Anarjan FS. Active targeting drug delivery nanocarriers: ligands. Nano-Struct Nano-Objects. 2019; 19:100370.

85. Egorova A, Selutin A, Maretina M, Selkov S, Baranov V, Kiselev A. Characterization of iRGD-ligand modified arginine-histidine-rich peptides for nucleic acid therapeutics delivery to αvβ3 integrin-expressing cancer cells. Pharmaceuticals (Basel). 2020; 13:300.

86. Javid H, Oryani MA, Rezagholinejad N, Esparham A, Tajaldini M, Karimi-Shahri M. RGD peptide in cancer targeting: benefits, challenges, solutions, and possible integrin-RGD interactions. Cancer Med. 2024; 13:e6800.

87. Long Q, Zhu W, Guo L, Pu L. RGD-conjugated resveratrol HSA nanoparticles as a novel delivery system in ovarian cancer therapy. Drug Des Devel Ther. 2020; 14:5747–56.

88. Liang X, Yang Y, Huang C, Ye Z, Lai W, Luo J, et al. cRGD-targeted heparin nanoparticles for effective dual drug treatment of cisplatin-resistant ovarian cancer. J Control Release. 2023; 356:691–701.

89. Dodda JM, Remiš T, Rotimi S, Yeh YC. Progress in the drug encapsulation of poly(lactic-co-glycolic acid) and folate-decorated poly(ethylene glycol)-poly(lactic-coglycolic acid) conjugates for selective cancer treatment. J Mater Chem B. 2022; 10:4127–41.

90. Liang C, Yang Y, Ling Y, Huang Y, Li T, Li X. Improved therapeutic effect of folate-decorated PLGA-PEG nanoparticles for endometrial carcinoma. Bioorg Med Chem. 2011; 19:4057–66.

91. Dana P, Bunthot S, Suktham K, Surassmo S, Yata T, Namdee K, et al. Active targeting liposome-PLGA composite for cisplatin delivery against cervical cancer. Colloids Surf B Biointerfaces. 2020; 196:111270.

92. Oladimeji O, Akinyelu J, Singh M. Co-polymer functionalised gold nanoparticles show efficient mitochondrial targeted drug delivery in cervical carcinoma cells. J Biomed Nanotechnol. 2020; 16:853–66.

93. Chen Y, Gao Y, Chen Y, Liu L, Mo A, Peng Q. Nanomaterials-based photothermal therapy and its potentials in antibacterial treatment. J Control Release. 2020; 328:251–62.

94. Wei W, Zhang X, Zhang S, Wei G, Su Z. Biomedical and bioactive engineered nanomaterials for targeted tumor photothermal therapy: a review. Mater Sci Eng C Mater Biol Appl. 2019; 104:109891.

95. Khan MS, Talib A, Pandey S, Bhaisare ML, Gedda G, Wu HF. Folic acid navigated silver selenide nanoparticles for photo-thermal ablation of cancer cells. Colloids Surf B Biointerfaces. 2017; 159:564–70.

96. Pandey S, Talib A, Mukeshchand Thakur M, Shahnawaz Khan M, Bhaisare ML, Gedda G, et al. Tellurium platinate nanowires for photothermal therapy of cancer cells. J Mater Chem B. 2016; 4:3713–20.

97. Zhang Y, Ang CY, Zhao Y. Polymeric nanocarriers incorporating near-infrared absorbing agents for potent photothermal therapy of cancer. Polym J. 2016; 48:589–603.

98. Zhang L, Chen S, Ma R, Zhu L, Yan T, Alimu G, et al. NIR-excitable PEG-modified au nanorods for photothermal therapy of cervical cancer. ACS Appl Nano Mater. 2021; 4:13060–70.

99. Zhang L, Alimu G, Du Z, Yan T, Li H, Ma R, et al. Functionalized magnetic nanoparticles for NIR-induced photothermal therapy of potential application in cervical cancer. ACS Omega. 2023; 8:21793–801.

100. Du Z, Ma R, Chen S, Fan H, Heng Y, Yan T, et al. A highly efficient polydopamine encapsulated clinical ICG theranostic nanoplatform for enhanced photothermal therapy of cervical cancer. Nanoscale Adv. 2022; 4:4016–24.

101. Yu H, He X, Zhou L, Chen L, Lu H, Wang J, et al. Exploring the potential of carbon-coated MoSe2 nanoparticles as a photothermal therapy for ovarian cancer. Arab J Chemy. 2024; 17:105495.

102. Liu B, Zhou J, Zhang B, Qu J. Synthesis of ag@ Fe₃O₄ nanoparticles for photothermal treatment of ovarian cancer. J Nanomater. 2019; 2019:6457968.

103. Yu Y, Tang D, Liu C, Zhang Q, Tang L, Lu Y, et al. Biodegradable polymer with effective near-infrared-II absorption as a photothermal agent for deep tumor therapy. Adv Mater. 2022; 34:2105976.

104. Jabir MS, Nayef UM, Abdulkadhim WK, Sulaiman GM. Supermagnetic Fe₃O₄-PEG nanoparticles combined with NIR laser and alternating magnetic field as potent anti-cancer agent against human ovarian cancer cells. Mater Res Express. 2019; 6:115412.

105. Chen W, Wang X, Zhao B, Zhang R, Xie Z, He Y, et al. CuS-MnS2 nano-flowers for magnetic resonance imaging guided photothermal/photodynamic therapy of ovarian cancer through necroptosis. Nanoscale. 2019; 11:12983–9.

106. Moses AS, Taratula OR, Lee H, Luo F, Grenz T, Korzun T, et al. Nanoparticle-based platform for activatable fluorescence imaging and photothermal ablation of endometriosis. Small. 2020; 16:e1906936.

107. Liu X, Yan S, Wu H, Chen M, Dai H, Wang Z, et al. Interventional hydrogel microsphere controlled‐releasing curcumin for photothermal therapy against endometriosis. Adv Funct Mater. 2024; 34:2315907.

108. Tian W, Wang C, Chu R, Ge H, Sun X, Li M. Injectable hydrogel nanoarchitectonics with near-infrared controlled drug delivery for in situ photothermal/endocrine synergistic endometriosis therapy. Biomater Res. 2023; 27:f100.

109. Guo X, Li W, Zhou J, Hou W, Wen X, Zhang H, et al. Specific photothermal ablation therapy of endometriosis by targeting delivery of gold nanospheres. Small. 2017; 13:1603270.

110. Li X, Lovell JF, Yoon J, Chen X. Clinical development and potential of photothermal and photodynamic therapies for cancer. Nat Rev Clin Oncol. 2020; 17:657–74.

111. Kessel D. Photodynamic therapy: apoptosis, paraptosis and beyond. Apoptosis. 2020; 25:611–5.

112. Shapshay SM. Endoscopic laser surgery handbook. In : Dougherty TJ, editor. Photodynamic therapy. 1st ed. Boca Raton: CRC Press;1987. p. 29.

113. Kwiatkowski S, Knap B, Przystupski D, Saczko J, Kędzierska E, Knap-Czop K, et al. Photodynamic therapy - mechanisms, photosensitizers and combinations. Biomed Pharmacother. 2018; 106:1098–107.

114. Verger A, Brandhonneur N, Molard Y, Cordier S, Kowouvi K, Amela-Cortes M, et al. From molecules to nanovectors: current state of the art and applications of photosensitizers in photodynamic therapy. Int J Pharm. 2021; 604:120763.

115. Luo X, Jia K, Xing J, Yi J. The utilization of nanotechnology in the female reproductive system and related disorders. Heliyon. 2024; 10:e25477.

116. Yu XT, Sui SY, He YX, Yu CH, Peng Q. Nanomaterials-based photosensitizers and delivery systems for photodynamic cancer therapy. Biomater Adv. 2022; 135:212725.

117. Tan G, Li W, Cheng J, Wang Z, Wei S, Jin Y, et al. Magnetic iron oxide modified pyropheophorbide-a fluorescence nanoparticles as photosensitizers for photodynamic therapy against ovarian cancer (SKOV-3) cells. Photochem Photobiol Sci. 2016; 15:1567–78.

118. Duse L, Agel MR, Pinnapireddy SR, Schäfer J, Selo MA, Ehrhardt C, et al. Photodynamic therapy of ovarian carcinoma cells with curcumin-loaded biodegradable polymeric nanoparticles. Pharmaceutic. 2019; 11:282.

119. Verger A, Dollo G, Brandhonneur N, Martinais S, Cordier S, Lang K, et al. PEGylated poly (lactic-co-glycolic acid) nanoparticles doped with molybdenum-iodide nanoclusters as a promising photodynamic therapy agent against ovarian cancer. Mater Adv. 2023; 4:3207–14.

120. Obaid G, Jin W, Bano S, Kessel D, Hasan T. Nanolipid formulations of benzoporphyrin derivative: exploring the dependence of nanoconstruct photophysics and photochemistry on their therapeutic index in ovarian cancer cells. J Photochem Photobiol. 2019; 95:364–77.

121. Michy T, Massias T, Bernard C, Vanwonterghem L, Henry M, Guidetti M, et al. Verteporfin-loaded lipid nanoparticles improve ovarian cancer photodynamic therapy in vitro and in vivo. Cancers (Basel). 2019; 11:176.

122. Alimu G, Yan T, Zhu L, Du Z, Ma R, Fan H, et al. Liposomes loaded with dual clinical photosensitizers for enhanced photodynamic therapy of cervical cancer. RSC Adv. 2023; 13:3459–67.